SubsidieMeestersGlycoengineered erythrocytes for better influenza vaccines
This project aims to validate glycan-engineered red blood cells for antigenic characterization of evolving influenza A/H3N2 viruses, enhancing seasonal vaccine development globally.
Projectdetails
Introduction
The objective of this ERC PoC project is to establish technical and commercial feasibility of our recently developed glycan-engineered red blood cells (RBCs) for antigenic characterization of circulating influenza A/H3N2 viruses.
Background
Due to the rapid evolution of influenza A/H3N2 viruses, antigenic characterization by the widely used hemagglutination inhibition (HI) assay is not possible anymore. Continuous antigenic characterization of influenza A viruses is, however, essential for the development of protective seasonal vaccines.
Project Development
The ERC program “sugar-enable” has developed glycoengineered RBCs that make it possible again to antigenically characterize circulating A/H3N2 viruses by the standard HI assay.
Expected Impact
It is expected that the cells will find application in hundreds of laboratories worldwide.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 29-2-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT UTRECHTpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Glyco-protein arrays for functional virus surveillanceThis project aims to assess the feasibility of glycan-protein arrays for early detection of pandemic influenza and coronavirus threats, enhancing public health surveillance. | ERC Proof of... | € 150.000 | 2024 | Details |
Diagnostic model and assay for personalized vaccineThis project aims to develop a diagnostic assay to predict influenza vaccine responsiveness in immunocompromised patients using identified biomarkers and machine learning models, enhancing personalized vaccination strategies. | ERC Proof of... | € 150.000 | 2025 | Details |
Broad-spectrum Antiviral siRNAs: Influenza Strains Targeted by AnticipationThe BARISTA project aims to develop a novel antiviral therapy for future influenza strains using optimized siRNA guided by NMR analysis, enhancing preparedness against emerging viruses. | ERC Proof of... | € 150.000 | 2025 | Details |
Structure and Function-based Design of Vaccine Antigens and Antiviral ImmunotherapiesThis project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses. | ERC Starting... | € 1.499.525 | 2025 | Details |
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolutionGlyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment. | ERC Starting... | € 1.500.000 | 2023 | Details |
Glyco-protein arrays for functional virus surveillance
This project aims to assess the feasibility of glycan-protein arrays for early detection of pandemic influenza and coronavirus threats, enhancing public health surveillance.
Diagnostic model and assay for personalized vaccine
This project aims to develop a diagnostic assay to predict influenza vaccine responsiveness in immunocompromised patients using identified biomarkers and machine learning models, enhancing personalized vaccination strategies.
Broad-spectrum Antiviral siRNAs: Influenza Strains Targeted by Anticipation
The BARISTA project aims to develop a novel antiviral therapy for future influenza strains using optimized siRNA guided by NMR analysis, enhancing preparedness against emerging viruses.
Structure and Function-based Design of Vaccine Antigens and Antiviral Immunotherapies
This project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses.
Isotopically labelling of cell surface glycans to illuminate infectious processes at atomic resolution
Glyco13Cell aims to chemically remodel cell surface glycans using NMR probes to enhance understanding of glycan-lectin interactions for developing novel tools in infectious disease treatment.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody DevelopmentDit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker. | Mkb-innovati... | € 153.020 | 2020 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Intracellular Carrier Against Resistant microOrganisms (ICARO)The ICARO project aims to enhance T cell responses against intracellular pathogens using silicon-based microchips for improved antigen presentation and novel vaccine development. | EIC Pathfinder | € 2.997.047 | 2022 | Details |
Micro array patches voor effectieve bestrijding infectieziektenDit project onderzoekt de haalbaarheid van vaccintoepassingen voor micro array technologie en ontwikkelt een roadmap voor veelbelovende vaccins tegen infectieziekten. | Mkb-innovati... | € 20.000 | 2020 | Details |
Het Rapid Response Vaccinatieplatform: Snel een epidemie onder controle krijgen door een snellere en efficiëntere vaccinatiemethode.Het project ontwikkelt een Rapid Response Vaccinatie Platform dat mRNA-vaccins via micronaalden pijnvrij en kosteneffectief toedient, om snel uitbraken wereldwijd te bestrijden. | Mkb-innovati... | € 350.000 | 2020 | Details |
From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody Development
Dit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
Intracellular Carrier Against Resistant microOrganisms (ICARO)
The ICARO project aims to enhance T cell responses against intracellular pathogens using silicon-based microchips for improved antigen presentation and novel vaccine development.
Micro array patches voor effectieve bestrijding infectieziekten
Dit project onderzoekt de haalbaarheid van vaccintoepassingen voor micro array technologie en ontwikkelt een roadmap voor veelbelovende vaccins tegen infectieziekten.
Het Rapid Response Vaccinatieplatform: Snel een epidemie onder controle krijgen door een snellere en efficiëntere vaccinatiemethode.
Het project ontwikkelt een Rapid Response Vaccinatie Platform dat mRNA-vaccins via micronaalden pijnvrij en kosteneffectief toedient, om snel uitbraken wereldwijd te bestrijden.